linjc16/ctgov huggingface dataset:
Use of Testicular Spermatozoa in Non-azoospermic Patients

Study Overview
=================
Brief Summary
-----------------
Use of testicular spermatozoa in non-azoospermic patients.

Detailed Description
-----------------
The aim of the study is to evaluate the characteristics of couples whose male partner is offered TESE after the failure of previous ICSI technique performed with ejaculated semen. All couples in a third-level University affiliated centre, between January 2010 and January 2020, whose male partner were diagnosed with any type of oligospermia and underwent TESE after ICSI from ejaculated semen, were included in the analysis.

Official Title
-----------------
Use of Testicular Spermatozoa in Non-azoospermic Patients: Retrospective Analysis of a Single Center Experience.

Conditions
-----------------
Male Infertility

Intervention / Treatment
-----------------
* Procedure: Testicular sperm extraction (TESE)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergone testiscular sperm extraction (TESE) after failure of ICSI with the use of ejaculated sperm Exclusion Criteria: Female age >40 yo

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Men who have undergone icsi from ejaculated semen<br> | |
| Men who have undergone icsi from testicular sperm<br> | Procedure: Testicular sperm extraction (TESE)<br>* During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fertilization rate (FR) | Evaluate if there is a higher fertilization rate in male patients undergone TESE | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blastulation rate (BR) | Evaluate if there is a higher blastulation rate in male patients undergone TESE | 10 years | 
| Miscarriage rate (MR) | Evaluate if there is a lower miscarriage rate in male patients undergone TESE | 10 years |
The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that native vitamin D will have more variability in 25(OH)D dose response when compared to a given equipotent dose of 25-hydroxyvitamin D3. This will be a single blind, active control, pharmacokinetic study of 625 μg 25(OH)D given orally or 2500 μg native vitamin D given orally.

Detailed Description
-----------------
Single blind, active control, pharmacokinetic study of 625 μg 25(OH)D given orally or 2500 μg native vitamin D given orally.

Official Title
-----------------
The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3 Compared to Native Vitamin D3: A Short Term Pharmacokinetic Study

Conditions
-----------------
Vitamin D Deficiency

Intervention / Treatment
-----------------
* Dietary Supplement: cholecalciferol
* Dietary Supplement: 25(OH)D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ten men and women in each group, aged 20-60. Exclusion Criteria: History of hypercalcemia, vitamin D supplement use > 800 IU daily, BMI > 30, gastrointestinal malabsorption (from celiac sprue, colitis, surgery, etc.), kidney disease or liver disease, use of steroids in any form, anticonvulsants, antibiotics, acute illness, or vacation planned to sunny climate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vitamin D Cholecalciferol<br>A single dose of 2500 micrograms cholecalciferol | Dietary Supplement: cholecalciferol<br>* a single dose of 2500 micrograms of cholecalciferol<br>|
| Experimental: 25(OH)D<br>A single dose of 625 micrograms 25(OH)D | Dietary Supplement: 25(OH)D<br>* a single dose of 625 micrograms of 25(OH)D<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum 25(OH)D response | 25(OH)D will be measured at frequent time intervals over 28 days. | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin D
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Study Overview
=================
Brief Summary
-----------------
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

Official Title
-----------------
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Conditions
-----------------
Hyperuricemia With or Without Gout

Intervention / Treatment
-----------------
* Drug: FYU-981
* Drug: Febuxostat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Serum urate level: >= 7.0mg/dL in patients with gouty nodule or with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type Outpatients Exclusion Criteria: Gouty arthritis within 14 days before randomized allocation Secondary hyperuricemia HbA1c: >= 8.4% Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease Kidney calculi or clinically significant urinary calculi AST: >= 100 IU/L or ALT: >= 100 IU/L eGFR: < 30 mL/min/1.73m^2 Systolic blood pressure: >= 180 mmHg or diastolic blood pressure: >= 110 mmHg

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FYU-981<br> | Drug: FYU-981<br>* Oral daily dosing for 14 weeks<br>|
| Active Comparator: Febuxostat<br> | Drug: Febuxostat<br>* Oral daily dosing for 14 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent reduction from baseline in serum urate level at the final visit | Percent reduction from baseline in serum urate level at the final visit | 14 weeks |
Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block

Study Overview
=================
Brief Summary
-----------------
This study aims to compare the alternative current and the direct current signal changes of photoplethysmography between both feet during one side lumbar sympathetic block. The hypothesis is that signal changes occur earlier than other indices to decide whether it is successful following lumbar sympathetic block on only one-side.

Official Title
-----------------
An Analysis of Photoplethysmographic Signal in Diagnostic Lumbar Sympathetic Block for Complex Regional Pain Syndrome

Conditions
-----------------
Complex Regional Pain Syndrome

Intervention / Treatment
-----------------
* Procedure: lumbar sympathetic block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physically examined for complex regional pain syndrome on lower extremity, Scheduled for diagnostic lumbar sympathetic blockade. Exclusion Criteria: Graded as ASA 3 or higher, Below 18 or above 70 years of age, or Had any other contraindication for regional anesthesia.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: lumbar sympathetic block<br>Unilateral lumbar sympathetic blockade using chirocaine | Procedure: lumbar sympathetic block<br>* unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy<br>* Other names: Chiba needle (Cook Inc., Bloomington, IN);|
| No Intervention: contralateral side<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Index of sympathetic block | change of slope of signals of the alternative current and the direct current from foot The baseline is defined as the point of surgical drap. The end of procedure is decided when the temperature of foot is increased more than 2 degrees from baseline within 20 minutes after local anesthetics injection | 1 minute at intervals from baseline through end of procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin temperature changes | foot temperature change from baseline | 1 minute at intervals during procedure | 
| electrocardiogram | heart rate variability measurement | 1 minute at intervals from baseline through end of procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
complex regional pain syndrome, lumbar sympathetic blockade, photoplethysmography, diagnostic lumbar sympathetic blockade